SGLT2 inhibitor side effects during surgery
Part of Hormones & metabolism clinical trials.
This study looks at how often a serious side effect called ketoacidosis (a build-up of acid in the blood) happens around the time of surgery in people taking SGLT2 inhibitors. By joining, you can help doctors learn how to better prevent and manage this risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been taking an SGLT2 inhibitor (a type of diabetes medicine) on a regular basis for the past 3 months or longer.
- You are having surgery, and you will need to stay in the hospital for at least one night after the procedure.
- You are 18 years old or older.
- You are willing and able to give your consent to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how stopping a common diabetes drug (SGLT2 inhibitor) affects the body's risk of a serious condition called ketoacidosis. It may help understand who is most at risk and how to prevent it.
This study tests whether using a dual continuous glucose and ketone monitor can help people with type 1 diabetes safely take a class of drugs called SGLT2 inhibitors, which may improve blood sugar control but can increase the risk of diabetic ketoacidosis (DKA). By closely monitoring changes in glucose and ketone levels, the study aims to prevent dangerous episodes while benefiting from the drug's effects.
This trial compares stopping or continuing your diabetes medication (SGLT-2 inhibitor) before heart surgery to see which approach is safer and better. It may help you and your doctor decide the best way to manage your medication around your operation.
This trial tests how stopping a type 2 diabetes medication called an SGLT2 inhibitor affects the liver's production of sugar and ketones. It may help understand better ways to manage diabetes.
This study tests how a drug called canagliflozin (an SGLT2 inhibitor) affects kidney function in people with type 2 diabetes. It involves two kidney biopsies to see how the drug works inside your kidneys, aiming to better protect kidney health.
This study tests whether a medicine called SGLT2i (a type of pill for kidney health) is safe and helpful for kidney transplant recipients who do not have diabetes. It aims to see if it can improve how the new kidney works.
Hear when a new SGLT2 Inhibitor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.